The United States Patent and Trademark Office recently granted the patents to the Los Angeles-based biotechnology firm, reinforcing the legal foundation for its clinical-stage programs. U.S. Patent No. 12,751,983 covers methods for treating Staphylococcus aureus infections using AP-SA02, while U.S. Patent No. 12,594,312 protects the company’s AP-PA02 program for addressing Pseudomonas infections. These additions bring Armata’s total global holdings to 101 issued patents and 60 pending applications.
In section Releases
Armata Pharmaceuticals Secures Long-Term Patent Protection for Phage Pipeline
Armata Pharmaceuticals has bolstered its intellectual property portfolio with two new U.S. patents covering its core bacteriophage programs, AP-SA02 and AP-PA02. These issuances, which extend protection for the company’s lead candidates through 2041 and beyond, solidify the firm’s competitive position in the development of therapies for antibiotic-resistant infections.
CEO Dr. Deborah Birx emphasized that these patents are central to the company’s strategy of shielding its proprietary phage platform from market competition. As Armata prepares to launch a Phase 3 superiority study for AP-SA02 later this year, the extended intellectual property runway provides critical stability. The company continues to advance its pipeline, targeting high-need areas like cystic fibrosis and complicated bacteremia, supported by a broad portfolio that now spans 15 patent families.
Comments (0)
No comments yet. Be the first!